Noroseal 2.6 g Intramammary Suspension for Cattle

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Bismuth subnitrate, heavy

제공처:

Norbrook Laboratories (Ireland) Limited

ATC 코드:

QG52X

INN (International Name):

Bismuth subnitrate, heavy

복용량:

2.6 g/syringe

약제 형태:

Intramammary suspension

처방전 유형:

LR: Licensed Retailer as defined in national legislation

치료 영역:

VARIOUS PRODUCTS FOR TEATS AND UDDER

승인 상태:

Authorised

승인 날짜:

2013-07-26

제품 특성 요약

Health Products Regulatory Authority
23 April 2019
CRN008XSP
Page 1 of 3
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Noroseal 2.6 g Intramammary Suspension for Cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
​
Each 4g Intramammary syringe contains:
​
​
Active substance:
​
​
Bismuth subnitrate, heavy
​
2.6g
​
For the full list of excipients, see section 6.1
​
3 PHARMACEUTICAL FORM
Intramammary suspension.
Light brown suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (dairy cows)
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Prevention of new intramammary infections throughout the dry period.
In cows considered likely to be free of sub-clinical mastitis, the
product may be suitable for use on its own in dry cow
management for mastitis control.
Selection of cows for treatment with the product should be based on
veterinary clinical judgement. Selection criteria may be
based on the mastitis and cell count history of individual cows, or
recognised tests for the detection of sub-clinical mastitis
such as bacteriological sampling.
4.3 CONTRAINDICATIONS
See section 4.7. Do not use in lactating cows. Do not use the product
alone in cows with sub-clinical mastitis at drying off. Do
not use in cows with clinical mastitis at drying off.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
(i) Special precautions for use in animals
It is good practice to observe dry cows regularly for signs of
clinical mastitis. If a sealed quarter develops clinical mastitis, the
affected quarter should be stripped out manually before appropriate
therapy is instituted.
To reduce the risk of contamination, do not immerse the syringe in
water.
Use the syringe only once.
It is important to observe strict aseptic technique for the
administration of the product, because the product does not have
antimicrobial activity.
Do not administer any other intramamma